Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. - Wikidata - awgldk - TriplyDB

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

http://www.wikidata.org/entity/Q35545219

about

N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase The endocannabinoid system as an emerging target of pharmacotherapy Endocannabinoids in the retina: from marijuana to neuroprotection Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain X-ray Crystallographic Analysis of α-Ketoheterocycle Inhibitors Bound to a Humanized Variant of Fatty Acid Amide Hydrolase Fluoride-Mediated Capture of a Noncovalent Bound State of a Reversible Covalent Enzyme Inhibitor: X-ray Crystallographic Analysis of an Exceptionally Potent α-Ketoheterocycle Inhibitor of Fatty Acid Amide Hydrolase Reversible Competitive α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long-Acting Analgesics Rational Design of Fatty Acid Amide Hydrolase Inhibitors That Act by Covalently Bonding to Two Active Site Residues Dual-Acting Compounds Targeting Endocannabinoid and Endovanilloid Systems-A Novel Treatment Option for Chronic Pain Management Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders Latest advances in the discovery of fatty acid amide hydrolase inhibitors Enzymatic pathways that regulate endocannabinoid signaling in the nervous system Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain Approximating protein flexibility through dynamic pharmacophore models: application to fatty acid amide hydrolase (FAAH)Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.α-Ketoheterocycle inhibitors of fatty acid amide hydrolase: exploration of conformational constraints in the acyl side chain.FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models.Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays.Drug addiction.The endocannabinoid system and pain Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.Inhibition of fatty acid amide hydrolase by kaempferol and related naturally occurring flavonoids.Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms.Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?Attenuation of cystitis and pain sensation in mice lacking fatty acid amide hydrolase Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study

P2860

Q24569817-1EDEA79A-4685-4EC5-B55F-8D4A51A162E1 Q24620186-150CC2B4-2D30-4F22-9D50-B6AE12A7B300 Q24648473-18C9C8BF-B9E7-42AF-8E4E-184BA157FADD Q24656049-C12FEAEF-153A-4B38-9F91-E5FD2BA1FA86 Q24673383-32BA703B-543F-4FD3-8DD8-60938CCD67DE Q24675554-93C3E2E0-3B8D-40FD-BF17-5EC0F7DE0D28 Q27655121-880C149A-3019-4B6C-A09E-4D7EB42F578C Q27658264-20D072A0-5F16-4D71-822F-4E8DCB665B2B Q27667078-BFEA2C17-76D6-4861-8FC7-C78660C5F262 Q27667312-DF709513-BF51-4D2C-9B45-04AA8D0587E9 Q27677344-2F8B8145-BA64-4DAF-BEF8-12CD8E0DE86A Q28067493-FC54AC6E-9B92-41E2-B264-5964E327DED3 Q28241318-07667739-AF3B-4F27-8E2A-2F4302B31936 Q28262282-00FA51B8-0F79-477C-AF57-CC4177F8783E Q28285103-8A0C3800-CB83-4E15-85D2-92866A431C1A Q28287173-41EDE38E-0A13-46F2-9479-83923F188E87 Q28390932-6035800F-4B52-4B9A-89EF-334FC5209516 Q28575056-429EB6E6-A3C5-458D-9314-E0BC2C164C19 Q28740837-45893365-5481-4B28-A60B-DAB6E1348C1C Q30574567-2DA425D4-1D2B-4E7A-B8E4-7F9CA943A6F5 Q33560467-88998694-CED9-4AD4-BA4A-80856116602D Q33644120-B7E27DBF-2DED-4569-9633-F7938D7CDCAD Q33956795-5DDC7A98-F28C-4AE9-8ECF-AD3C3CAE03F4 Q34019573-1871C0FA-C0BF-4304-9212-10990FAC0CA5 Q34027721-DA9C15CB-50BD-4E8F-8320-907B3B98E0C4 Q34173626-92F7B9F5-14CE-4DC2-AA39-D38A5077CC8D Q34179408-5DF5DA67-8DA0-4D20-B89E-799B623728F5 Q34390806-D4C8E031-71CF-49F3-B83C-EDCF5B82F134 Q34442314-A810A9B6-8E38-4783-B73D-7DFA7678E909 Q34575484-B0A52840-12CD-4F1D-B620-3593ABA52F74 Q34612917-2E2B64E3-3F30-44D5-92B6-774A21D7EE7A Q34644485-2F5C0148-9E3D-4609-B85B-61AF97E1495E Q34786464-570431F6-53ED-4EAC-9060-4474D0751365 Q34801735-49313638-DBBB-49BE-A242-6F52DE9EDF0B Q34953319-4A7D6564-F95E-42D9-89B4-886E40CFFD9D Q35030056-77E2DBC6-B3B6-4BBA-A3CE-F40AE2F6A162 Q35163541-AA9F3776-EAC2-42E4-B877-225B5CE9B395 Q35189004-4AA0FF9E-F3CE-4797-BADB-B1B0F4969000 Q35689152-EBF3029B-864B-4C79-A917-4131E848DC3E Q36056312-D41CFB49-6591-4A88-9B0F-DA4FC201AF12

P2860

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

http://www.wikidata.org/entity/Q35545219

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

@ast

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

@en

type

label

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

@ast

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

@en

prefLabel

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

@ast

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

@en

P1433

Q35545219-67B0573E-09C0-46DB-8EDD-9FF74F0C6754

P1476

Q35545219-D64F7B8D-0761-4A21-B87A-B92B3CEE891D

P2093

Q35545219-32901046-5BA9-450E-84C4-2F4FDA9B70C8

Q35545219-3DD3C053-4CD1-4E3D-82FC-839C4DE9CC35

Q35545219-5EE2E78D-7B5E-4B7B-BEDC-B2A50B5680C4

Q35545219-95A7F854-4889-4D02-A624-74FDABC8A3FC

Q35545219-BB53EF1C-D8B0-4301-970E-4522C65121C7

P2860

Q35545219-0F641613-78D8-4A4A-9E9E-E5895501FA20

Q35545219-10EA6CF2-BAB0-4646-A83F-F2F2A46E789E

Q35545219-13822785-521D-442C-AB37-548292E31BF1

Q35545219-2FDAAEC3-6505-430D-B93A-44C7110854DC

Q35545219-302AE1B7-A324-4AE0-BFBB-BA3CD8158583

Q35545219-31844CB4-F0A3-4AB2-9401-9ADE2AFE1E87

Q35545219-324E36E6-AE86-45C9-A0E3-1B293ED14733

Q35545219-3E92CE72-031F-486F-A47C-34E4D249E61F

Q35545219-3FD122CF-331F-448C-BA21-25AF926522C7

Q35545219-46589854-3114-4E14-8B1B-4F08388D514D

P304

Q35545219-A8E0183F-1239-4477-9B81-BD78BDC2A066

P31

Q35545219-8D401EAB-7378-4B66-889B-43333BFD6ED5

P356

Q35545219-0D022BE6-9990-4D22-B38E-5C0E9357FBDE

P407

Q35545219-EE111521-E4E5-435B-B05B-89F6E2267B67

P433

Q35545219-590179E8-EEC7-4FBF-B329-AECC382D77E5

P478

Q35545219-2D8C903E-4C72-47FC-B6D6-1421E4242A73

P50

Q35545219-158DD193-C300-469A-8AC5-D4C2A76B10D1

P577

Q35545219-B3F39C7D-78FC-4024-805D-E06B002F4938

P5875

Q35545219-14D72D8B-83F4-4C88-B3BF-7B610F8D6B9A

P698

Q35545219-6DA53C8B-583C-4FD8-A663-98FFCBC25921

P921

Q35545219-EF8EA9BB-9B13-4842-A54A-1C5FBFBCC31B

Q35545219-a839da7d-9f67-48c2-ac2f-9fbbb4cb13ba

Q35545219-bcf04d9d-1042-41d3-8fa7-942c104acfc4

P932

Q35545219-38CC7425-F597-4FA2-907B-C7D64327F0E1

P356

P1433

British Journal of Pharmacology

P1476

Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.

@en

P2093

Angelo Jayamanne

http://www.w3.org/2001/XMLSchema#string

Daniele Piomelli

http://www.w3.org/2001/XMLSchema#string

Ruth Greenwood

http://www.w3.org/2001/XMLSchema#string

Sevda Aslan

http://www.w3.org/2001/XMLSchema#string

Vanessa A Mitchell

http://www.w3.org/2001/XMLSchema#string

P2860

Brain monoglyceride lipase participating in endocannabinoid inactivation

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain

Impaired nociception and pain sensation in mice lacking the capsaicin receptor

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

P304

281-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0706510

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

147

http://www.w3.org/2001/XMLSchema#string

P50

Christopher W Vaughan

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7438835

http://www.w3.org/2001/XMLSchema#string

P698

16331291

http://www.w3.org/2001/XMLSchema#string

P921

neuropathic pain

chronic neuropathic pain

P932

1751298

http://www.w3.org/2001/XMLSchema#string